AbbVie
ABBV
#31
Rank
$322.43 B
Marketcap
$182.10
Share price
0.97%
Change (1 day)
15.07%
Change (1 year)

The biotechnology and pharmaceutical company Abbvie, spelled AbbVie, was founded in 2013 as a spin-off from Abbott Laboratories and is traded on the NYSE stock exchange in the S&P 100 index under the symbol โ€œABBVโ€.

P/E ratio for AbbVie (ABBV)

P/E ratio as of March 2024 (TTM): 49.5

According to AbbVie's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 49.475. At the end of 2022 the company had a P/E ratio of 24.3.

P/E ratio history for AbbVie from 2012 to 2023

PE ratio at the end of each year

Year P/E ratio Change
202224.316.29%
202120.9-43.89%
202037.2122.84%
201916.7-35.26%
201825.8-11.41%
201729.170.28%
201617.1-8.47%
201518.7-68.3%
201458.9188.94%
201320.492.03%
201210.6

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
14.9-69.84%๐Ÿ‡บ๐Ÿ‡ธ USA
143 189.62%๐Ÿ‡บ๐Ÿ‡ธ USA
20.1-59.39%๐Ÿ‡บ๐Ÿ‡ธ USA
11.7-76.39%๐Ÿ‡บ๐Ÿ‡ธ USA
16.7-66.27%๐Ÿ‡บ๐Ÿ‡ธ USA
13.7-72.39%๐Ÿ‡บ๐Ÿ‡ธ USA
34.1-31.01%๐Ÿ‡ฌ๐Ÿ‡ง UK
12.2-75.25%๐Ÿ‡ฌ๐Ÿ‡ง UK
70.4 42.23%๐Ÿ‡บ๐Ÿ‡ธ USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.